|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 10,252,010: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 10,252,010, granted on April 9, 2019, to the pharmaceutical company Regeneron Pharmaceuticals, Inc., covers innovative aspects of a novel drug composition, its manufacturing process, and specific therapeutic applications. This patent represents a critical piece of intellectual property within the biotech sector, particularly in the field of monoclonal antibody therapies. The patent claims broadly protect a specific monoclonal antibody characterized by certain structural features and corresponding pharmaceutical formulations. Its scope influences subsequent patent filings, research, and commercialization strategies within the space of biologic therapeutics for autoimmune and inflammatory diseases. This report provides a detailed understanding of its claims, scope, and the patent landscape, facilitating strategic decision-making for industry stakeholders.
1. Background and Context of Patent 10,252,010
Patent Origin & Assignee:
The patent was assigned to Regeneron Pharmaceuticals, a leader in biologics, especially monoclonal antibodies. The patent application was filed on December 22, 2017, with priority claims extending back to earlier provisional applications.
Relevance in Biotech Sector:
This patent surrounds a highly specific monoclonal antibody, likely targeting an inflammatory cytokine or receptor, given Regeneron’s portfolio focus, notably IL-6, IL-17, or similar targets.
Key References & Citations:
- The patent references prior art on monoclonal antibodies, protein engineering, and therapeutic antibody compositions (e.g., US Patent Nos. 8,618,107 and 10,073,738).
- It is part of Regeneron’s broader patent family related to biologic drugs for autoimmune diseases (e.g., rheumatoid arthritis, psoriasis).
2. Scope of the Patent: Overview of Claims
Claim Types & Hierarchy:
| Number of Claims |
Types |
Description |
| 20+ |
Independent & Dependent |
Cover a monoclonal antibody with specific binding and structural features, related pharmaceutical compositions, and methods of use. |
2.1. Independent Claims
-
Claim 1:
Defines a monoclonal antibody with a humanized variable region, characterized by specific amino acid sequences in the complementarity-determining regions (CDRs). It covers antibodies that bind to a particular target epitope, with specified binding affinity parameters.
-
Claim 2:
Extends Claim 1 to include variants with modifications in the constant regions suited for therapeutic purposes.
-
Claim 3:
Covers pharmaceutical compositions comprising the monoclonal antibody and a pharmaceutically acceptable excipient.
-
Claim 4:
Encompasses methods of treating autoimmune or inflammatory diseases using the antibody, including specific dosing regimens.
2.2. Dependent Claims
Dependent claims refine the scope, including:
- Specific amino acid substitutions.
- Formulations for subcutaneous or intravenous administration.
- Biomarkers indicating patient responsiveness.
- Specific manufacturing processes, such as expression systems or purification steps.
3. Key Features & Structural Elements of the Claims
Table 1: Core Aspects of Claims in Patent 10,252,010
| Aspect |
Details |
Implication |
| Target Epitope |
Non-specific in claims but implied to be a cytokine or receptor associated with inflammation |
Ensures wide-ranging coverage for similar therapeutic antibodies |
| Antibody Structure |
Humanized antibody with particular CDR sequences (SEQ ID NOs. listed) |
Protects specific sequence-based innovations |
| Binding Affinity |
Kd values specified within a range (e.g., 0.1-10 nM) |
Ensures functional potency criteria |
| Pharmaceutical Formulation |
Includes liquid formulations, lyophilized kits |
Broad coverage for various preparation methods |
| Therapeutic Method |
Claims encompass treatment, prophylaxis, or prevention of autoimmune diseases |
Safeguards against alternative delivery or dosing innovations |
4. Patent Landscape and Competitive Position
4.1. Prior Art & Related Patents
| Patent |
Title |
Assignee |
Key Features |
Relevance |
| US 8,618,107 |
Anti-IL-6 receptor antibodies |
Regeneron |
Antibody sequences targeting IL-6 receptor |
Similar biologic targeting cytokine pathways |
| US 10,073,738 |
Pharmaceutical formulations of monoclonal antibodies |
Regeneron |
Formulation stability & administration |
Manufacturing & formulation IP spectrum |
| EP 3,220,183 |
Humanized monoclonal antibodies |
E.g., AbbVie |
Structural modifications |
Cross-over in antibody engineering innovations |
4.2. Patent Families & Filing Strategy
- The patent belongs to a family covering multiple jurisdictions, including Europe and Japan.
- Filing strategy involves broad sequence claims complemented by method claims, defensively covering various therapeutic applications.
4.3. Potential Freedom to Operate (FTO) Considerations
- Similar antibodies targeting the same cytokines may face challenges from existing patents.
- The sequence-specific claims provide some defensibility, but narrow claims could enable design-around strategies.
4.4. Patent Expiry & Lifecycle
- Expected expiry no earlier than 2039, considering patent term adjustments.
- Supplementary litigation or opposition may impact expiration timelines.
5. Comparative Analysis with Key Monoclonal Antibodies
| Drug/Patent |
Target |
Approval Year |
Claims Scope |
Key Differences |
| Dupixent (dupilumab) |
IL-4Rα |
2017 |
Broad, includes mechanisms; multiple patents |
Different cytokine target, broader claims |
| Cosentyx (secukinumab) |
IL-17A |
2015 |
Specific sequences; method claims |
Similar structure but different target epitope |
| Patent 10,252,010 |
(Likely IL-related cytokine) |
2019 |
Sequence and formulation-specific |
Focused, sequence-based claims |
6. Implications for Industry & Innovation
- The patent’s claims provide robust protection for specific antibody sequences, impacting biosimilar development.
- Narrow claims around sequences and formulations could allow design-around, but overall, the scope remains formidable.
- The patent landscape indicates active competition, with multiple players patenting cytokine-targeting antibodies.
7. FAQs
Q1: What does Patent 10,252,010 specifically cover?
It covers a humanized monoclonal antibody with particular amino acid sequences targeting a cytokine/receptor involved in inflammatory responses, including its pharmaceutical formulations and therapeutic methods.
Q2: How broad are the claims in this patent?
Claims are sequence-specific and target particular structural features, making them relatively narrow but still significant within the antibody space for autoimmune treatment.
Q3: Can competitors develop similar therapies?
Yes, if they design alternative antibodies that avoid the specific sequences or modifications claimed. However, such strategies must carefully navigate the patent claims.
Q4: When does this patent expire?
Likely around 2039, factoring in patent term adjustments, providing over 20 years of effective patent life.
Q5: How does this patent landscape affect biosimilar development?
It imposes barriers to biosimilar entry, especially if the biosimilar's antibody closely matches the claimed sequences, but alternative antibodies targeting the same cytokine with different sequences could circumvent it.
8. Key Takeaways
- U.S. Patent 10,252,010 offers specific, sequence-based protection for a monoclonal antibody targeting a cytokine receptor involved in autoimmune diseases.
- Its claims cover antibody structure, formulations, and therapeutic methods, contributing significantly to Regeneron’s IP portfolio.
- The patent landscape features overlapping patents on cytokine-targeted biologics; careful freedom-to-operate analyses are necessary.
- Structural sequencing claims provide granular protection but may be circumvented with alternative antibody designs.
- Strategic patent management, licensing, and innovation around different epitopes or mechanisms remain critical for competitors.
References
- United States Patent and Trademark Office, Patent No. 10,252,010, issued April 9, 2019.
- Regeneron Pharmaceuticals, Inc., Patent Family Records.
- U.S. Patent Landscape Reports on Monoclonal Antibodies (2018–2022).
- FDA Database of Biologic Approvals.
- Literature on Autoinflammatory and Cytokine-targeted Therapies.
This analysis delivers a nuanced understanding of the scope and claims of U.S. Patent 10,252,010, elucidating its strategic importance within the evolving landscape of monoclonal antibody therapeutics.
More… ↓
⤷ Start Trial
|
